Analysis of the effectiveness of anemia correction in CKD stage 5 on the basis of the "V.A. Baranov Republican Hospital" in Karelia Republic

BACKGROUND. Nephrogenic anemia is a serious problem in patients with chronic kidney disease, requiring a careful approach and adequate treatment. This condition manifests at the first stage and steadily progresses as GFR decreases. Therefore, timely correction of renal anemia with iron supplements and erythropoiesis stimulate agents (ESA) in CKD C5 is an integral component of therapy to reach target Hb values.

THE AIM. This paper provides an analysis of the effectiveness of erythropoiesis-stimulating therapy among patients with end-stage CKD (C5d) receiving treatment with program hemodialysis on the basis of the Republican hospital named V.A. Baranov.

PATIENTS AND METHODS. During the year 2022, 107 patients with end-stage CKD were observed. All of them had been receiving renal replacement therapy through a hemodialysis program (1284 patientmonths) and erythropoiesis-stimulating therapy with monthly monitoring of hemoglobin levels, following the clinical guidelines «Anemia in chronic kidney disease – 2020-2021-2022».

RESULTS. The median hemoglobin level for 2022 was 107.8 g/L. The average annual increase was 8.9 g/l. Overall, the hemoglobin level in patients who did not receive EPO was 115.5 g/l. Patients receiving EPO who did not reach the target hemoglobin level (IR: 100-120 g/L) had a median hemoglobin of 92.5 g/L. To achieve the presented levels of anemia correction, the average weekly dose was 6,785 IU when calculated for the entire year 2022, including those patient months when EPO was not used.

CONCLUSIONS. During treatment with EPO drugs, an increase in hemoglobin levels is observed, patients' quality of life improves, the risks of cardiovascular complications decrease, performance and physical endurance increase, the frequency and duration of hospitalizations decrease, and the need for blood transfusions decreases. The main challenges in solving the problem of refractory anemia involve individualizing treatment, considering drug response, and identifying additional factors.

1. Chronic kidney disease. Diagnostics and treatment. Pod red C. Yana, W. He; lane from English edited by A. V. Smirnova. GEOTARMEDIA, M., 2022. 448 s. doi: 10.33029/9704-6498-4CKD-2022-1-44

2. Kotenko ON, Abolyan LV, Kuteynikov VYu et al. Anemia and quality of life of patients with chronic kidney disease on renal replacement therapy using program hemodialysis. Therapeutic archive 2023;95(1):32–37. doi: 10.26442/00403660.2023.01.202050

3. Shilo VYu, Gorin AA, Denisov AYu. Quality of life of patients on hemodialysis: connection with achieving the target hemoglobin level. Abstracts of the IV conference of the RDO. Nephrology and dialysis 2005;7(7):303

4. Clinical guidelines «Anemia in chronic kidney disease» 2020–2021–2022 (05/31/2021) – Approved by the Ministry of Health of the Russian Federation

5. Shilo VYu et al. Association of Nephrologists of Russia Russian Dialysis Society, Scientific Society of Nephrologists of Russia. National recommendations “Diagnostics and treatment of anemia in chronic kidney disease” [Electronic resource]. 2014

6. Smirnov AV [et al.].Clinical guidelines. Chronic kidney disease (CKD). Nephrology 2021;25(5):10–84. doi:10.36485/1561-62742021-25-5-10-84

7. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney inter., Suppl. 2012

8. Poselyugina OB, Markina AD, Panasenko AS. prognostic value of nephrogenic anemia. Modern approaches to its diagnosis and treatment. Modern problems of science and education 2021;(3). doi: 10.17513/spno.30815

9. Anemia in chronic kidney disease: current problems and new treatment options. Scientific and practical conference “Healthy kidneys for everyone”. Effective pharmacotherapy. Urology and nephrology 2022;(18)27

10. Chizh KA. Internal diseases today: collection. scientific tr., dedicated 100th anniversary of the BSMU “Anemia in chronic kidney disease.”

11. Shostka GD. Anaemia in renal failure. Nephrology (SaintPetersburg) 1997;1(4):12–18. (In Russ.) doi: 10.24884/15616274-1997-1-4-12-18

12. Pavlov AD et al. Erythropoiesis, erythropoietin, iron. GEOTARMEDIA, M., 2011, 304 s. ISBN 978-5-9704-1986-1

13. Nair S, Trivedi M. Anemia management in dialysis patients: a PIVOT and a new path? Curr Opin Nephrol Hypertens 2020; 29(3):351–355. doi: 10.1097/MNH.0000000000000607

14. Zemchenkov AYu, Gerasimchuk RP, Sabodash AB, Vishnevsky KA, Konakova IN, Kulaeva NN, Staroselsky KG, Timokhovskaya GYu, Isachkina AN, Sour PN, Zhdanova IV, Beketov VV, Vasilyeva GV, Solovyova OM, Komandenko SA, Fomenko AM, Rumyantsev AS. Anemia in patients with CKD 5: current trends in the world and the picture in St. Petersburg. Nephrology and dialysis 2017; 19(3):371–381. doi: 10.28996/1680-4422-2017-3-371-381

15. Bikbov B, Bieber B, Andrusev A, Tomilina N, Zemchenkov A, Zhao J, Port F, Robinson B, Pisoni R. Hemodialysis practice patterns in the Russia Dialysis Outcomes and Practice Patterns Study (DOPPS), with international comparisons. Hemodial Int 2017;21(3): 393–408. doi: 10.1111/hdi.12503